{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:55:03Z","timestamp":1793876103899,"version":"4.7.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ajo.2024.12.012","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T11:18:22Z","timestamp":1734434302000},"page":"130-140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["The Role of Intravitreal Chemotherapy as an Adjunctive Treatment for Retinoblastoma: A Systematic Review and Single-Arm Meta-Analysis"],"prefix":"10.1016","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6744-8529","authenticated-orcid":false,"given":"ANDRES","family":"BRAVO-GONZALEZ","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PABLO","family":"DOMINGUEZ-RUIZ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MAR\u00cdA","family":"GONZ\u00c1LEZ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SARA","family":"HIRA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CLAUDIA","family":"AVIL\u00c9S-COVARRUBIAS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CARLOS EDUARDO DE MENEZES E","family":"SOUZA-FILHO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MARIANA TOSATO","family":"ZINHER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CAROL L.","family":"SHIELDS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ajo.2024.12.012_bib0001","first-page":"1","article-title":"Global retinoblastoma presentation and analysis by national income level","volume":"6","author":"Fabian","year":"2020","journal-title":"JAMA Oncol"},{"issue":"14","key":"10.1016\/j.ajo.2024.12.012_bib0002","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/jnci\/85.14.1121","article-title":"Mortality from second tumors among long-term survivors of retinoblastoma","volume":"85","author":"Eng","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.ajo.2024.12.012_bib0003","article-title":"Ten-year experience with ophthalmic artery chemosurgery: Ocular and recurrence-free survival","volume":"13","author":"Jh","year":"2018","journal-title":"PloS one"},{"issue":"8","key":"10.1016\/j.ajo.2024.12.012_bib0004","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.ophtha.2007.12.014","article-title":"A phase I\/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results","volume":"115","author":"Abramson","year":"2008","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2024.12.012_bib0005","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s10384-015-0378-0","article-title":"Intravitreal injection of melphalan for intraocular retinoblastoma","volume":"59","author":"Suzuki","year":"2015","journal-title":"Jpn J Ophthalmol"},{"issue":"12","key":"10.1016\/j.ajo.2024.12.012_bib0006","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/S0161-6420(85)34105-2","article-title":"Tumor seeding in ocular fine needle aspiration biopsy","volume":"92","author":"Karcioglu","year":"1985","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.ajo.2024.12.012_bib0007","article-title":"Profiling safety of intravitreal injections for retinoblastoma using an anti-reflux procedure and sterilisation of the needle track","volume":"96","author":"Fl","year":"2012","journal-title":"The British journal of ophthalmology"},{"issue":"5","key":"10.1016\/j.ajo.2024.12.012_bib0008","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3928\/01913913-20160719-04","article-title":"Retinoblastoma control with primary intra-arterial chemotherapy: outcomes before and during the intravitreal chemotherapy era","volume":"53","author":"Shields","year":"2016","journal-title":"J Pediatr Ophthalmol Strabismus"},{"issue":"4","key":"10.1016\/j.ajo.2024.12.012_bib0009","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.ophtha.2016.12.015","article-title":"Efficacy and toxicity of intravitreous chemotherapy for retinoblastoma: four-year experience","volume":"124","author":"Francis","year":"2017","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.ajo.2024.12.012_bib0010","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.ophtha.2014.03.028","article-title":"Local and systemic toxicity of intravitreal melphalan for vitreous seeding in retinoblastoma: a preclinical and clinical study","volume":"121","author":"Francis","year":"2014","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2024.12.012_bib0011","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1167\/iovs.12-9466","article-title":"Intra-ophthalmic artery chemotherapy triggers vascular toxicity through endothelial cell inflammation and leukostasis","volume":"53","author":"Steinle","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"10.1016\/j.ajo.2024.12.012_bib0012","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/aos.12990","article-title":"Toxic effects of melphalan, topotecan and carboplatin on retinal pigment epithelial cells","volume":"94","author":"S\u00fcsskind","year":"2016","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2024.12.012_bib0013","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1159\/000510506","article-title":"Intravenous chemotherapy for retinoblastoma in the era of intravitreal chemotherapy: a systematic review","volume":"7","author":"Raval","year":"2021","journal-title":"Ocul Oncol Pathol"},{"key":"10.1016\/j.ajo.2024.12.012_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104423","article-title":"Safety of intravitreal chemotherapy in the management of retinoblastoma: a systematic review of the literature","volume":"200","author":"Lavasidis","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.ajo.2024.12.012_bib0015","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000536410","article-title":"Evidence in focus: the sparse landscape of randomized trials on retinoblastoma treatment","volume":"10","author":"Lavasidis","year":"2024","journal-title":"Ocular Oncol Pathol"},{"key":"10.1016\/j.ajo.2024.12.012_bib0016","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions. Accessed October 15, 2024. https:\/\/training.cochrane.org\/handbook\/current"},{"issue":"10","key":"10.1016\/j.ajo.2024.12.012_bib0017","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.ophtha.2024.04.022","article-title":"Intravitreal topotecan for vitreous seeds in retinoblastoma: a long-term review of 91 eyes","volume":"131","author":"Sen","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2024.12.012_bib0018","article-title":"High-dose intravitreal topotecan for recurrent retinoblastoma, subretinal seeds, and vitreous seeds in 13 consecutive cases","author":"Shields","year":"2024","journal-title":"Retina"},{"issue":"4","key":"10.1016\/j.ajo.2024.12.012_bib0019","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/APO.0000000000000360","article-title":"Outcomes of intravenous chemotherapy (chemoreduction) for retinoblastoma based on patient age in 964 Eyes of 554 patients","volume":"10","author":"Bas","year":"2021","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"issue":"2","key":"10.1016\/j.ajo.2024.12.012_bib0020","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/bjophthalmol-2020-318529","article-title":"Evaluation of intravitreal topotecan dose levels, toxicity and efficacy for retinoblastoma vitreous seeds: a preclinical and clinical study","volume":"106","author":"Bogan","year":"2022","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"10.1016\/j.ajo.2024.12.012_bib0021","first-page":"1273","article-title":"Anterior segment complications and globe salvage following intravitreal or periocular chemotherapy for intraocular retinoblastoma","volume":"64","author":"King","year":"2023","journal-title":"Invest Ophthalmol Visual Sci"},{"issue":"4","key":"10.1016\/j.ajo.2024.12.012_bib0022","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s10384-020-00743-2","article-title":"Comparison of intravitreal melphalan with and without topotecan in the management of vitreous disease in retinoblastoma","volume":"64","author":"Kiratli","year":"2020","journal-title":"Jpn J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2024.12.012_bib0023","doi-asserted-by":"crossref","first-page":"778","DOI":"10.4103\/IJO.IJO_2414_23","article-title":"Retinoblastoma - a comprehensive review, update and recent advances","volume":"72","author":"Nag","year":"2024","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.ajo.2024.12.012_bib0024","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.2147\/OPTH.S417370","article-title":"Ocular survival following intravitreal melphalan as adjuvant treatment for vitreous retinoblastoma seeding","volume":"17","author":"Alahmadi","year":"2023","journal-title":"Clin Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2024.12.012_bib0025","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3109\/13816810.2014.973045","article-title":"Classification and management of seeds in retinoblastomaellsworth lecture Ghent august 24th 2013","volume":"35","author":"Munier","year":"2014","journal-title":"Ophthalmic Genet"},{"issue":"2","key":"10.1016\/j.ajo.2024.12.012_bib0026","doi-asserted-by":"crossref","first-page":"119","DOI":"10.17219\/acem\/166180","article-title":"Efficacy of intravitreal injections of melphalan in the treatment of retinoblastoma vitreous seeding","volume":"33","author":"Cie\u015blik","year":"2024","journal-title":"Adv Clin Exp Med"},{"issue":"10","key":"10.1016\/j.ajo.2024.12.012_bib0027","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archophthalmol.2012.1983","article-title":"Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma","volume":"130","author":"Ghassemi","year":"2012","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2024.12.012_bib0028","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/ICU.0000000000000091","article-title":"Targeted retinoblastoma management: when to use intravenous, intra-arterial, periocular, and intravitreal chemotherapy","volume":"25","author":"Shields","year":"2014","journal-title":"Curr Opin Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2024.12.012_bib0029","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000491580","article-title":"Primary intra-arterial chemotherapy for retinoblastoma in the intravitreal chemotherapy era: five years of experience","volume":"5","author":"Dalvin","year":"2019","journal-title":"Ocul Oncol Pathol"},{"issue":"4","key":"10.1016\/j.ajo.2024.12.012_bib0030","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/bjophthalmol-2018-312037","article-title":"Intravitreal chemotherapy in retinoblastoma: expanded use beyond intravitreal seeds","volume":"103","author":"Abramson","year":"2019","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2024.12.012_bib0031","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1136\/bjophthalmol-2013-303188","article-title":"Evaluating the risk of extraocular tumour spread following intravitreal injection therapy for retinoblastoma: a systematic review","volume":"97","author":"Smith","year":"2013","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2024.12.012_bib0032","doi-asserted-by":"crossref","first-page":"e28845","DOI":"10.1002\/pbc.28845","article-title":"Retinoblastoma management in 13q deletion syndrome patients using super-selective chemotherapies and other cancer-directed interventions","volume":"68","author":"Cobbs","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.ajo.2024.12.012_bib0033","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/IAE.0000000000002782","article-title":"Toxicity and efficacy of intravitreal melphalan for retinoblastoma: 25\u00b5g vs 30\u00b5g","volume":"41","author":"Liao","year":"2021","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.ajo.2024.12.012_bib0034","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1186\/s12885-024-12058-3","article-title":"Characteristics of patients with recurrent retinoblastoma: a survival analysis","volume":"24","author":"Li","year":"2024","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.ajo.2024.12.012_bib0035","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1159\/000491432","article-title":"Precision intravitreal chemotherapy for localized vitreous seeding of retinoblastoma","volume":"5","author":"Yu","year":"2019","journal-title":"Ocul Oncol Pathol"},{"issue":"6","key":"10.1016\/j.ajo.2024.12.012_bib0036","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1159\/000509080","article-title":"Intravitreal melphalan for retinoblastoma: the impact of toxicity on recurrence and ultimate globe salvage","volume":"6","author":"Berry","year":"2020","journal-title":"Ocul Oncol Pathol"},{"issue":"12","key":"10.1016\/j.ajo.2024.12.012_bib0037","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1001\/jamaophthalmol.2017.4600","article-title":"Risk of extraocular extension in eyes with retinoblastoma receiving intravitreous chemotherapy","volume":"135","author":"Francis","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ajo.2024.12.012_bib0038","first-page":"445","article-title":"Safety and Efficacy of Posterior Sub-Tenon's Carboplatin Injection versus Intravitreal Melphalan Therapy in the Management of Retinoblastoma with Secondary Vitreous Seeds","volume":"11","author":"Said","year":"2018","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.ajo.2024.12.012_bib0039","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12886-019-1059-4","article-title":"Ocular Toxicity of Intravitreal Melphalan for Retinoblastoma in Chinese Patients","volume":"19","author":"Xue","year":"2019","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.ajo.2024.12.012_bib0040","first-page":"e11757","article-title":"Outcomes of Group D Retinoblastoma With Resistant Vitreous Seeds After Integration of Intravitreal Chemotherapy to the Treatment Protocol","volume":"12","author":"Amin","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.ajo.2024.12.012_bib0041","doi-asserted-by":"crossref","first-page":"257","DOI":"10.18240\/ijo.2020.02.09","article-title":"Combined Intra-Arterial Chemotherapy and Intravitreal Melphalan for the Treatment of Advanced Unilateral Retinoblastoma","volume":"13","author":"Liang","year":"2020","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.ajo.2024.12.012_bib0042","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1177\/1120672120957587","article-title":"Secondary Intra-Arterial Chemotherapy and\/or Intravitreal Chemotherapy as Salvage Treatment for Retinoblastoma","volume":"31","author":"Mirzayev","year":"2021","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.ajo.2024.12.012_bib0043","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.ophtha.2020.09.021","article-title":"Risk Factors for Acute Choroidal Ischemia after Intra-Arterial Melphalan for Retinoblastoma: The Role of the Catheterization Approach","volume":"128","author":"Stathopoulos","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2024.12.012_bib0044","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000511980","article-title":"Eye Salvage with Intra-Arterial and Intra-Vitreal Chemotherapy in Patients with Retinoblastoma: 8-Year Single-Institution Experience in Colombia","volume":"7","author":"Gonz\u00e1lez","year":"2021","journal-title":"Ocul Oncol Pathol"},{"key":"10.1016\/j.ajo.2024.12.012_bib0045","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.phoj.2020.10.002","article-title":"Outcomes of Intravitreal Melphalan for Vitreous Seedings in Retinoblastoma Resistant to Systemic Chemotherapy","volume":"6","author":"Khaqan","year":"2021","journal-title":"Pediatric Hematology Oncology Journal"},{"key":"10.1016\/j.ajo.2024.12.012_bib0046","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/2474126420951980","article-title":"Vitreous Seed Classification and Regression Patterns in Eyes With Retinoblastoma","volume":"5","author":"Rishi","year":"2020","journal-title":"J Vitreoretin Dis"},{"key":"10.1016\/j.ajo.2024.12.012_bib0047","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.696787","article-title":"Safety and Efficacy of Intravitreal Chemotherapy (Melphalan) to Treat Vitreous Seeds in Retinoblastoma","volume":"12","author":"Yousef","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ajo.2024.12.012_bib0048","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1159\/000520952","article-title":"Combination of Brachytherapy and Intravitreal Chemotherapy in the Treatment of Retinoblastoma with Vitreous Seeding","volume":"8","author":"Schl\u00fcter","year":"2022","journal-title":"Ocul Oncol Pathol"},{"key":"10.1016\/j.ajo.2024.12.012_bib0049","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00417-022-05903-3","article-title":"Addition of Intravitreal Carboplatin with Melphalan for Management of Vitreous Seeding in Retinoblastoma","volume":"261","author":"Riazi-Esfahani","year":"2023","journal-title":"Graefes Arch Clin Exp Ophthalmol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939424005683?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939424005683?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T16:47:17Z","timestamp":1777567637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939424005683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":49,"alternative-id":["S0002939424005683"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2024.12.012","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of Intravitreal Chemotherapy as an Adjunctive Treatment for Retinoblastoma: A Systematic Review and Single-Arm Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2024.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}